Johnson & Johnson stated late Thursday that preliminary data shows its single-shot vaccine is efficient against the fast-spreading Delta variant of COVID-19 that was first found in India.
In a statement, the New Jersey-based firm stated that its vaccine generated an immune response against the variant that lasted no less than eight months. J&J added that its vaccine induced extra antibody exercise against the Delta variant than against the Beta variant, which was first positioned in South Africa, although the dose labored against all so-called “variants of concern.”
The firm stated the data got here from two small sub-studies that have been offshoots of its authentic vaccine trial. Both research, which examined vaccine recipients’ blood, had been submitted for publication.
“Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally,” stated J&J Chief Scientific Officer Dr. Paul Stoffels in a press release. “We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant. This adds to the robust body of clinical data supporting our single-shot vaccine’s ability to protect against multiple variants of concern.”
“Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,” added Dr. Mathai Mammen, the top of analysis and improvement for Johnson & Johnson’s pharmaceutical division. “In addition, we observe a persistent and particularly robust, durable cellular immune response. With each new dataset, we build on our solid foundation of evidence that our single-shot COVID-19 vaccine plays a critical role in ending the pandemic, which continues to evolve and pose new challenges to global health.”
The announcement follows an announcement earlier this week by Moderna that its mRNA vaccine had produced antibodies against a number of coronavirus variants, together with the Delta pressure, in a lab examine. A separate examine revealed in the journal Nature prompt mRNA vaccines produced by Moderna and Pfizer might present “persistent” safety against COVID-19 for years — supplied the virus doesn’t mutate an excessive amount of past its present kinds.
On Wednesday, Centers for Disease Control and Prevention (CDC) Director Dr. Rochelle Walensky said fully vaccinated Americans are “quite protected from the variants that we have circulating here in the United States” and reiterated that these individuals don’t have to put on a masks.
That got here on the heels of a advice by Los Angeles County health officials for individuals to renew carrying masks in indoor public areas, no matter their vaccination standing, because of a rise in circumstances blamed on the variant.
Walensky additionally advised NBC’s “Today” present that Americans who acquired the J&J vaccine seemingly don’t want to return for a booster shot, a press release supported by the preliminary data introduced Thursday.
“We have every reason to believe, based on how J&J is performing with other variants of concern – and that is quite well – and how its sister vaccine, AstraZeneca, has performed against the Delta variant in other countries … people are agreeing that they anticipate that the J&J will perform well against the Delta variant, as it has so far against other variants circulating in the United States,” she stated.